Wei Dong

VP, Drug Safety at Denali Therapeutics

Wei builds and leads our safety and pharmacovigilance organization. In this role, she oversees the scientific, operational and product strategy aspects of global safety during clinical development and will enable our teams, and the organization as a whole, to address future marketing authorization applications and multinational postmarketing safety requirements.

Wei brings extensive R&D experience in global drug development to improve patient care. She held executive leadership roles in Genentech and Roche in the areas of drug safety, epidemiology and Asia Pacific product development contributing to the approval of several breakthrough medicines. Most recently she served as the Vice President and Head of Safety at Corcept Therapeutics building up its safety team and ensuring successful regulatory inspections.

Wei obtained her MD from Shanghai Medical University and PhD in Occupational Epidemiology from the London School of Hygiene & Tropical Medicine, University of London. She lectured at UCL Medical School, U.K., and was an Assistant Professor of Epidemiology and Community Medicine at Mount Sinai School of Medicine before joining the industry.

Timeline

  • VP, Drug Safety

    Current role

View in org chart